SystImmune/BMS and Hengrui showcase ADC data for EGFR-mutant lung cancer at ESMO

At the European Society for Medical Oncology (ESMO) meeting in Madrid, Li Zhang of Sun Yat-sen University Cancer Center presented early data from the HERON‑Lung01 study, highlighting an antibody‑drug conjugate (ADC) approach for patients with EGFR‑mutant non‑small cell lung cancer who have progressed after AstraZeneca’s Tagrisso.

The presentation underscored a growing competition among ADC developers to capture this niche market, with Chinese companies taking a leading role in the research and development effort.

While detailed efficacy and safety results were not disclosed in the brief report, the data suggest that ADCs remain a focal point of interest for addressing resistance mechanisms in EGFR‑mutant lung cancer.